157 related articles for article (PubMed ID: 23435842)
1. Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.
Kawano A; Nakajima TE; Oda I; Hokamura N; Iwasa S; Kato K; Hamaguchi T; Yamada Y; Fujii H; Shimada Y
Gastric Cancer; 2014 Jan; 17(1):54-60. PubMed ID: 23435842
[TBL] [Abstract][Full Text] [Related]
2. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of endoscopic resection and metachronous cancer after endoscopic resection for adenocarcinoma of the esophagogastric junction in Japan.
Abe S; Ishihara R; Takahashi H; Ono H; Fujisaki J; Matsui A; Takahashi A; Goda K; Kawada K; Koike T; Takeuchi M; Tsuji Y; Hirasawa D; Oyama T
Gastrointest Endosc; 2019 Jun; 89(6):1120-1128. PubMed ID: 30576649
[TBL] [Abstract][Full Text] [Related]
4. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia.
Nunobe S; Nakanishi Y; Taniguchi H; Sasako M; Sano T; Kato H; Yamagishi H; Sekine S; Shimoda T
Pathol Int; 2007 Jun; 57(6):315-21. PubMed ID: 17539961
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
6. Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.
Zhang X; Watson DI; Jamieson GG
Chin Med J (Engl); 2007 Dec; 120(24):2268-70. PubMed ID: 18167216
[TBL] [Abstract][Full Text] [Related]
7. Tumor size predicts worse prognosis in esophagogastric junction adenocarcinoma.
Takeda FR; Ramos MFKP; Pereira MA; Sallum RAA; Ribeiro Junior U; Nahas SC; Cecconello I
Updates Surg; 2022 Dec; 74(6):1871-1879. PubMed ID: 35776245
[TBL] [Abstract][Full Text] [Related]
8. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
9. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and associated factors of Japanese patients with adenocarcinoma of the esophagogastric junction: a multicenter clinicoepidemiological study.
Matsueda K; Manabe N; Toshikuni N; Sato Y; Watanabe T; Yamamoto H; Haruma K
Dis Esophagus; 2017 Jun; 30(6):1-6. PubMed ID: 28475744
[TBL] [Abstract][Full Text] [Related]
11. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction.
Kudou K; Saeki H; Nakashima Y; Kimura K; Ando K; Oki E; Ikeda T; Maehara Y
World J Surg; 2019 Apr; 43(4):1068-1075. PubMed ID: 30478682
[TBL] [Abstract][Full Text] [Related]
13. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
[TBL] [Abstract][Full Text] [Related]
14. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
[TBL] [Abstract][Full Text] [Related]
15. Association of Helicobacter pylori and gastric atrophy with adenocarcinoma of the esophagogastric junction in Taixing, China.
Gao P; Cai N; Yang X; Yuan Z; Zhang T; Lu M; Jin L; Ye W; Suo C; Chen X
Int J Cancer; 2022 Jan; 150(2):243-252. PubMed ID: 34498732
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
17. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
[TBL] [Abstract][Full Text] [Related]
18. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction.
Yoshikawa T; Takeuchi H; Hasegawa S; Nozaki I; Kishi K; Ito S; Ohi M; Mine S; Hara J; Matsuda T; Hiki N; Kurokawa Y
Gastric Cancer; 2016 Jan; 19(1):143-9. PubMed ID: 25414051
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
